Latest Articlesddd

Array: Selumetinib Negative Results Are No Match to Its Binimetinib Positive Results

August 9, 2016 0

We do expect some selling of Array today after AstraZeneca’s announced negative results from Phase 3 …

Why BMY News Is Not As Bad As Hysterical Investors Believed

August 5, 2016 0

ANOTHER MISLEADING STORY  This article was corrected after being posted. Read our apology at the end …

Plummeted Firms That Offer Good Investment Opportunities Are Filling the Place

August 3, 2016 0

Investors in the stock market know that stocks yo-yo all the time. Sometimes, the yo-yoing becomes …

Adaptimmune EMA Privileges. Different Fate for Plummeting Stocks

August 1, 2016 0

EMA’s created Priority Medicines (PRIME) regulatory initiative for products which the European agency rules they are …

Answering Readers Questions About the Possible Outcome of Valeant Pharmaceuticals’ Psoriasis Drug

July 19, 2016 0

The FDA advisory committee members’ inability to rule for or against the approval of Valeant (VRX) …

Coming from AstraZeneca and Juno: News That Makes a Big Difference

July 18, 2016 0

Important news is the news that informs about successful achievements that make a difference in treating …

NOVOCURE: The FDA Approves the Firm’s Second Generation Non-Invasive Treatment for Glioblastoma

July 15, 2016 0

News about approvals or insinuations about almost guaranteed future approvals of products that promise improving the …

The FDA Approves INSIGHTEC’s Non-Invasive Approach That Treats Tremors. Humans Can Make Miracles Too.

July 15, 2016 0

The FDA approved INSIGHTEC firm’s Exablate Neuro system for the non-invasive treatment of essential tremor (ET) …

JUNO Surged After the FDA Removed the Clinical Hold of the ROCKET Trial. See Also: Why SAGE Surged

July 13, 2016 0

JUNO   Juno Therapeutics (JUNO), the CAR T developing firm that aims at revolutionizing cancer treatment …

Why Amgen Is Still King. Why Roche Allergic Asthma Drug Xolair Is Becoming a Blockbuster.

July 11, 2016 0

AMGEN Repatha is the human monoclonal antibody that blocks a protein called proprotein convertase subtilisin/kexin type …

JUNO: The CAR-T Approach Is Still a Source of Hope for Cancer Patients Who Have Lost It

July 8, 2016 0

Juno Therapeutics (JUNO) announced that the U.S. Food and Drug Administration (FDA) has placed a clinical …

Biotech Firms with Guaranteed Growth Potential

July 7, 2016 0

Good news is not always great news that makes a difference. In the drug industry, clinical …

Oncolytic Adenovirus Plus Opdivo Could Be a Game Changer in Late Stage Cancer. See Also: Gossip Surrounds Tesaro

July 5, 2016 0

PsiOxus Therapeutics’ adenovirus product in combination with Opdivo (nivo-lumab) for late-stage cancers.     Bristol-Myers Squibb (BMY) …

Tesaro: The Time Has Come for Bringing Hope to Recurrent Ovarian Cancer Patients

July 1, 2016 0

- Tesaro's (TSRO) drug niraparib significantly improved progression-free survival for patients with ovarian cancer in both …

The Royal Divorce. Gilead Rallied Not Plummeted

June 29, 2016 0

The Royal Divorce On Sunday, the next day after the announcement of the British referendum’s results, …

Ignoring Incyte’s Successive Good News Will Fail to Mislead Investors

June 27, 2016 0

GRAFT VERSUS HOST DISEASE (GVHD) INCYTE (INCY) HAS SEVERAL GOOD NEWS. As a matter of fact, …

Le CompaGnon Part 2

June 23, 2016 0

Le CompaGnon Part 2 Wednesday June 22, 2016 From the  American Society of  Clinical  Oncology (ASCO)               …

The Biotech Sector Evolution in the News

June 22, 2016 0

Innoviva (INVA) and GlaxoSmithKline plc (GSK) announced positive results from the pivotal Phase 3 FULFIL study …

Paratek Antibiotic Omadacycline Meets Primary Endpoint in Resistant Infection

June 20, 2016 0

Paratek Pharmaceuticals (PRTK) announced positive results from Phase 3 registration study comparing its once-daily, broad spectrum …

Ariad Pharmaceuticals Submits Early NDA for the Approval of Brigatinib. See Also: More News from Ariad

June 17, 2016 0

ARIAD Pharmaceuticals (ARIA) announced the initiation of a New Drug Application (NDA) submission for brigatinib, the …